Teladoc Health Inc (NYSE:TDOC) SVP Andrew Turitz sold 8,202 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $64.14, for a total value of $526,076.28. Following the completion of the sale, the senior vice president now owns 9,378 shares in the company, valued at $601,504.92. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Teladoc Health stock traded down $1.59 on Friday, reaching $54.22. 22,998 shares of the company’s stock were exchanged, compared to its average volume of 1,340,719. The stock has a market capitalization of $4.19 billion, a price-to-earnings ratio of -32.72 and a beta of 0.92. Teladoc Health Inc has a 52 week low of $30.88 and a 52 week high of $89.05. The company has a debt-to-equity ratio of 0.40, a quick ratio of 8.99 and a current ratio of 8.99.
Teladoc Health (NYSE:TDOC) last posted its quarterly earnings results on Thursday, November 1st. The health services provider reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.02. The firm had revenue of $111.00 million for the quarter, compared to analysts’ expectations of $109.94 million. Teladoc Health had a negative return on equity of 14.05% and a negative net margin of 31.32%. The company’s revenue for the quarter was up 61.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.55) EPS. On average, equities research analysts forecast that Teladoc Health Inc will post -1.47 EPS for the current year.
Several analysts recently commented on TDOC shares. SunTrust Banks upped their target price on Teladoc Health to $77.00 and gave the company a “buy” rating in a report on Thursday, August 9th. Jefferies Financial Group set a $90.00 target price on Teladoc Health and gave the company a “buy” rating in a report on Friday, September 28th. Citigroup reiterated a “buy” rating and issued a $95.00 target price on shares of Teladoc Health in a report on Friday, September 28th. Canaccord Genuity upped their target price on Teladoc Health from $86.00 to $94.00 and gave the company a “buy” rating in a report on Friday, September 28th. Finally, Craig Hallum upped their target price on Teladoc Health from $70.00 to $80.00 and gave the company a “buy” rating in a report on Monday, October 15th. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $85.06.
Several large investors have recently modified their holdings of the company. Marshall Wace North America L.P. raised its position in shares of Teladoc Health by 313.5% during the third quarter. Marshall Wace North America L.P. now owns 202,001 shares of the health services provider’s stock worth $17,443,000 after purchasing an additional 153,146 shares during the period. Reynders McVeigh Capital Management LLC raised its position in Teladoc Health by 2.8% in the 3rd quarter. Reynders McVeigh Capital Management LLC now owns 145,529 shares of the health services provider’s stock valued at $12,566,000 after buying an additional 3,930 shares during the last quarter. Diversified Trust Co purchased a new stake in Teladoc Health in the 3rd quarter valued at $237,000. Vanguard Group Inc. raised its position in Teladoc Health by 26.9% in the 3rd quarter. Vanguard Group Inc. now owns 5,874,182 shares of the health services provider’s stock valued at $507,236,000 after buying an additional 1,244,388 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Teladoc Health by 13.5% in the 3rd quarter. Legal & General Group Plc now owns 24,669 shares of the health services provider’s stock valued at $2,131,000 after buying an additional 2,943 shares during the last quarter.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
See Also: Swap
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.